Assembly Biosciences Announces Presentation at International Association for the Study of the Liver Congress and Update on HBV Program in China
Assembly Biosciences, Inc. (ASMB)
Last assembly biosciences, inc. earnings: 3/4 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.assemblybio.com/investor-relations
Company Research
Source: GlobeNewswire
SAN FRANCISCO, June 21, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced that Richard Colonno, PhD, Executive Vice President, Chief Scientific Officer, Virology Operations, will present at the first International Association for the Study of the Liver (IASL) Congress on June 22, 2019 in Beijing. “We are excited to have the opportunity to highlight our HBV Cure program during the inaugural IASL Congress in Beijing and provide an update on our business activities in China, including drug development efforts in the country. Hepatitis B is considered a major health threat in China, with more than 90 million people living with the infection. It is clear that nucleos(t)ide therapy alone is not capable of completely eliminating viral replication and infection, but the addition of a core inhibitor,
Show less
Read more
Impact Snapshot
Event Time:
ASMB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ASMB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ASMB alerts
High impacting Assembly Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
ASMB
News
- Assembly Biosciences, Inc. (NASDAQ: ASMB) had its "neutral" rating re-affirmed by analysts at HC Wainwright.MarketBeat
- Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B [Yahoo! Finance]Yahoo! Finance
- Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis BGlobeNewswire
- Assembly Biosciences Announces $30.1 Million Equity Investment and Accelerated Funding from Gilead to Advance Clinical Development Programs [Yahoo! Finance]Yahoo! Finance
- Assembly Biosciences Announces $30.1 Million Equity Investment and Accelerated Funding from Gilead to Advance Clinical Development ProgramsGlobeNewswire
ASMB
Earnings
- 5/8/24 - Beat
ASMB
Analyst Actions
- 12/27/24 - HC Wainwright
ASMB
Sec Filings
- 2/14/25 - Form SCHEDULE
- 1/3/25 - Form 8-K
- 12/31/24 - Form 4
- ASMB's page on the SEC website